{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:45:23Z","timestamp":1773301523792,"version":"3.50.1"},"reference-count":37,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3201,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title><jats:bold>Introduction:<\/jats:bold><\/jats:title><jats:p>Many patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitors have residual symptoms (eg, persistent fatigue, excessive sleepiness) despite an overall antidepressant response. Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Methods:<\/jats:bold><\/jats:title><jats:p>This 12-week, open-label, dose titration, extension study followed an 8-week placebo-controlled study of modafinil augmentation in patients with MDD. The dose was 100\u2013400 mg\/day. The median stable dose was 300 mg\/day. Assessments were the Epworth Sleepiness Scale, Brief Fatigue Inventory, Clinical Global Impression of Improvement scale, 17-item Hamilton Rating Scale for Depression, and Montgomery-\u00c5sberg Depression Rating Scale.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Results:<\/jats:bold><\/jats:title><jats:p>Of the 245 patients treated, 194 completed the study; 70% reported Clinical Global Impression of Improvement scale responses of \u201cmuch improved\u201d or \u201cvery much improved\u201d between open-label baseline and final visit (previous randomized modafinil group: 74%; placebo group: 66%). When data were analyzed for four subsets of patients (former modafinil responders, placebo responders, modafinil nonresponders, and placebo nonresponders), improvements in scores on all outcome measures were at least twice as great among former modafinil and placebo nonresponders compared with responders. Most common adverse events were headache (18%), nausea (9%), and dizziness (7%); all were generally mild to moderate in severity.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Conclusion:<\/jats:bold><\/jats:title><jats:p>Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852900010622","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T22:02:03Z","timestamp":1444773723000},"page":"93-102","source":"Crossref","is-referenced-by-count":47,"title":["Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: <i>A 12-Week, Open-label, Extension Study<\/i>"],"prefix":"10.1017","volume":"11","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"DeBattista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod J.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900010622_ref033","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.6.1181"},{"key":"S1092852900010622_ref036","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00213-002-1080-8","article-title":"Study of the addictive potential of modafinil in naive and cocaine-experienced rats","volume":"161","author":"Deroche-Gamonet","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"S1092852900010622_ref020","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0510"},{"key":"S1092852900010622_ref032","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0212"},{"key":"S1092852900010622_ref028","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"S1092852900010622_ref027","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"S1092852900010622_ref025","first-page":"179","volume-title":"ECDEU Assessment Manual for Psychopharmacology Revised Edition","author":"Hamilton","year":"1976"},{"key":"S1092852900010622_ref024","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0112"},{"key":"S1092852900010622_ref018","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1996.6.537"},{"key":"S1092852900010622_ref016","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145700001887"},{"key":"S1092852900010622_ref023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0911"},{"key":"S1092852900010622_ref021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0910"},{"key":"S1092852900010622_ref011","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-003-0430-9"},{"key":"S1092852900010622_ref004","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(02)00226-9"},{"key":"S1092852900010622_ref030","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S1092852900010622_ref026","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"S1092852900010622_ref001","first-page":"1245","article-title":"How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria","volume":"48","author":"Maurice-Tison","year":"1998","journal-title":"Br J Gen Pract"},{"key":"S1092852900010622_ref035","first-page":"183","article-title":"Differential effects of a new central adrenergic agonist\u2014modafinil\u2014and D-amphetamine on sleep and early morning behaviour in young healthy volunteers","volume":"9","author":"Saletu","year":"1989","journal-title":"Int J Clin Pharmacol Res"},{"key":"S1092852900010622_ref012","first-page":"41","article-title":"Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders","volume":"59","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852900010622_ref006","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00138-4"},{"key":"S1092852900010622_ref031","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0812"},{"key":"S1092852900010622_ref019","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200304000-00017"},{"key":"S1092852900010622_ref013","first-page":"269","article-title":"An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression","volume":"54","author":"Joffe","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"S1092852900010622_ref009","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900002236"},{"key":"S1092852900010622_ref003","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0403"},{"key":"S1092852900010622_ref002","first-page":"139","article-title":"DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee","volume":"14","author":"Tylee","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"S1092852900010622_ref017","doi-asserted-by":"publisher","DOI":"10.3109\/15622970109027495"},{"key":"S1092852900010622_ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83028-3"},{"key":"S1092852900010622_ref034","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00015-3"},{"key":"S1092852900010622_ref029","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"S1092852900010622_ref008","first-page":"20","article-title":"Clinical issues in long-term treatment with antidepressants","volume":"61","author":"Zajecka","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"S1092852900010622_ref010","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)00135-P"},{"key":"S1092852900010622_ref022","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104910.75206.b9"},{"key":"S1092852900010622_ref005","first-page":"30","article-title":"Symptoms of fatigue and cognitive\/executive dysfunction in major depressive disorder before and after antidepressant treatment","volume":"64","author":"Fava","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S1092852900010622_ref037","doi-asserted-by":"publisher","DOI":"10.1080\/10401230490453743"},{"key":"S1092852900010622_ref015","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80071-5"},{"key":"S1092852900010622_ref014","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199812000-00009"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900010622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:02:58Z","timestamp":1556910178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900010622\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S1092852900010622"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900010622","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}